Recombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders
AssigneerEVO Biologics, Inc.
InventorsHarry M. Meade, Paul R. Bourdon
Life of this patent
Estimating the term…
Abstract
In one aspect, the disclosure relates to compositions comprising alpha-1-antitrypsin (AAT) and the production thereof. In some embodiments, the AAT is recombinantly produced. The disclosure also relates to methods of administering compositions comprising alpha-1-antitrypsin (AAT).
Claims22
A composition comprising alpha-1-antitrypsin (AAT), wherein the AAT is recombinantly produced.
A composition comprising AAT wherein the AAT has a high level of deoxyhexose glycosylation.
A composition comprising AAT wherein the AAT has a high level of sialylation on the AAT-glyco-motifs.
A composition comprising AAT wherein the AAT has a high level of deoxyhexose glycosylation and a high level of sialylation on the AAT-glyco-motifs.
Dependencies are inferred from the claim text.